Exploring the sex difference in cardiovascular risk during growth hormone therapy in adults
Authors' conclusion
Our results suggest that men with GHD did indeed experience more beneficial effects of GHRT on body composition and lipoprotein metabolism than women, at least in the early years of treatment. Also, the more unfavourable CV risk profile at baseline in men did not translate into a sex difference in the risk of developing CV and cerebrovascular morbidity during GHRT.
Study context
- Population
- Adults with severe growth hormone deficiency (GHD) registered in the Dutch National Registry of GH Treatment in Adults database, receiving GH replacement therapy
- Participants
- 1,335 vs 1,251
- Exposure
- Men vs women with severe GHD on GH replacement therapy
- Menn = 1,335
- Womenn = 1,251reference
- Outcome
- Sex-specific differences in efficacy of (long-term) GH replacement therapy on CV risk profile and disease
Methodological detailsnationwide
- Nationwide
Main finding
As reported in the abstract
CV risk profile changes during GH replacement therapy · first years of GH replacement therapy
- Reduction in waist circumference, waist-to-hip ratio, total cholesterol and TG greater in men than in women (all P < .05)
- Between-sex differences in effects during later follow-up less clear
Observational data: associations, not effects.
Further findings
Cardiovascular (CV) risk profile at baseline
- Men had a more unfavourable CV risk profile at baseline
Non-fatal cardiovascular or cerebrovascular diseases during GH replacement therapy
- No sex differences in risk of developing non-fatal cardiovascular or cerebrovascular diseases
Original publication
Exploring the sex difference in cardiovascular risk during growth hormone therapy in adults. Eur J Endocrinol. Published 27 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →